Your browser doesn't support javascript.
loading
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial.
Scholtes, Rosalie A; Mosterd, Charlotte M; Hesp, Anne C; Smits, Mark M; Heerspink, Hiddo J L; van Raalte, Daniël H.
Afiliação
  • Scholtes RA; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Mosterd CM; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Hesp AC; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Smits MM; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Heerspink HJL; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • van Raalte DH; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
Diabetes Obes Metab ; 25(1): 198-207, 2023 01.
Article em En | MEDLINE | ID: mdl-36089810

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Losartan / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials Limite: Aged / Humans / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Losartan / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials Limite: Aged / Humans / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda País de publicação: Reino Unido